The PrEP Costing Guidelines provide a framework for estimating the cost of providing pre-exposure prophylaxis (PrEP), which is the use of antiretroviral (ARV) drugs for preventing the acquisition of HIV infection.
As part of its Monitoring, Evaluation, and Reporting (MER) guidance, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) released Version 2.3 in September 2018, which includes revised indicators for orphans and vulnerable children (OVC) programs.
With funding from PEPFAR, the Human Resources for Health in 2030 (HRH2030) has developed, piloted, and field-tested a tool to help health facility staff and district health management teams optimize their health workforce for the roll-out of “Test and Start” utilizing
This article reflects on the social, political, and structural factors that shape risk and influence access to prevention and care. It calls for the use of a collection of indicators that incorporate principles of human rights, gender equality, and participation, recognizing that without equity, epidemic transition cannot truly be achieved or sustained.
In most developing economies particularly in Africa, more people are likely to die of HIV/AIDS and malaria compared to other diseases. HIV/AIDS tends to be superimposed on the long standing malaria burden particularly in sub-Saharan Africa. The detection and understanding of spatial overlaps in disease occurrence is important for integrated and targeted disease control. Integrated disease control can enhance efficiency and cost-effectiveness through the development of drugs targeting multiple infections in the same geographic space.
Undetectable = untransmittable is the message of a new UNAIDS Explainer. With 20 years of evidence demonstrating that HIV treatment is highly effective in reducing the transmission of HIV, the evidence is now clear that people living with HIV with an undetectable viral load cannot transmit HIV sexually.